APR 246

Drug Profile

APR 246

Alternative Names: APR-246; PRIMA-1-MET

Latest Information Update: 14 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aprea
  • Developer Aprea; H. Lee Moffitt Cancer Center and Research Institute; Jules Bordet Institute; Peter MacCallum Cancer Centre; Victorian Cancer Agency
  • Class Antineoplastics; Quinuclidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Thioredoxin reductase inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Malignant melanoma; Myelodysplastic syndromes; Oesophageal cancer
  • Preclinical Lung cancer
  • No development reported Haematological malignancies; Prostate cancer

Most Recent Events

  • 13 Aug 2018 Aprea Therapeutics completes a phase I/II trial Malignant melanoma (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Belgium (IV) (NCT03391050) (EudraCT2017-002577-18)
  • 19 Jul 2018 Groupe Francophone des Myelodysplasies and Aprea Therapeutics plans a phase I/II trial for Acute myeloid leukaemia, Chronic myelomonocytic leukaemia, Myelodysplastic syndromes (Combination therapy, Second-line therapy or greater) in France in September 2018 (NCT03588078)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top